Concepedia

Mari Nakata

MN

Statistics

Publications

8

Citations

205

H-Index

8

Active since

2008

Affiliations

Astellas Pharma (Japan)(Current)

Mari Nakata is an author at Astellas Pharma (Japan) specializing in pharmacology, medicine, and cancer research.

Top concepts

Publications per year

2008–2022

8

Publications

8

Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma

Aya Kita, Takahito Nakahara, Kentaro Yamanaka et al. · Leukemia Research · 2011 · 58 citations

, , +8

Effects of serotonin 5‐HT<sub>3</sub> receptor antagonists on stress‐induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer

Tetsuya Hirata, Yoshihiro Keto, Mari Nakata et al. · Neurogastroenterology & Motility · 2008 · 46 citations

Sepantronium Bromide (YM155) Enhances Response of Human B-Cell Non-Hodgkin Lymphoma to Rituximab

Aya Kita, Keisuke Mitsuoka, Naoki Kaneko et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 31 citations

Effects of serotonin 5-HT3 receptor antagonists on CRF-induced abnormal colonic water transport and defecation in rats

Takuya Hirata, Yoshihiro Keto, Mari Nakata et al. · European Journal of Pharmacology · 2008 · 16 citations

, , +4

Abstract A227: Antitumor activities of ASP3026 against EML4-ALK-dependent tumor models.

Sadao Kuromitsu, Masamichi Mori, Itsuo Shimada et al. · Molecular Cancer Therapeutics · 2011 · 16 citations

, , +15

1–5 of 8